Dabrafenib in the treatment of metastatic or unresectable melanoma

Leila Khoja, David Hogg

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Dabrafenib is a potent inhibitor of mutant BRAF. Trials to date have shown it to be well tolerated, with significant activity in unresectable stage III or IV metastatic melanoma. Overall response rates of approximately 50% were seen in addition to improved progression-free and overall survival of 6 and 18 months, respectively. Preclinical studies suggested that combining BRAF and MEK inhibition would increase response rates and decrease toxicity. Clinical trials with the combination of dabrafenib and trametinib have improved progression-free and overall survival in interim analyses. Future improvements in responses and outcomes will depend on additional combination strategies, possibly employing immunotherapy.

Original languageEnglish
Pages (from-to)265-276
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number3
Publication statusPublished - 25 Feb 2015


  • Animals
  • Antineoplastic Agents/adverse effects
  • Disease-Free Survival
  • Humans
  • Imidazoles/adverse effects
  • Melanoma/drug therapy
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Oximes/adverse effects
  • Protein Kinase Inhibitors/adverse effects
  • Skin Neoplasms/drug therapy
  • Survival Rate
  • BRAF
  • dabrafenib
  • efficacy
  • metastatic melanoma
  • toxicity
  • trametinib


Dive into the research topics of 'Dabrafenib in the treatment of metastatic or unresectable melanoma'. Together they form a unique fingerprint.

Cite this